Related Experiment Video

Updated: Jun 10, 2026

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema

Tom Bowen1, Marco Cicardi, Henriette Farkas

  • 1Departments of Medicine and Paediatrics, University of Calgary, Calgary, Alberta, Canada. tbowen@pol.net.

Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology
|July 30, 2010
PubMed

Insights

This study updates the 2010 International Consensus Algorithm for diagnosing and managing Hereditary Angioedema (HAE). The consensus provides an interim guide for this complex disorder, emphasizing the need for evidence-based guidelines from clinical trials.

Area of Science:

  • Immunology
  • Genetics
  • Clinical Medicine

Background:

  • Previous consensus algorithms for Hereditary Angioedema (HAE) were published in 2003 and updated in 2007.
  • HAE is characterized by C1 inhibitor (C1-INH) deficiency.

Purpose of the Study:

  • To update the International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema (HAE) as of 2010.

Main Methods:

  • A conference was held in Toronto, Canada, on May 15-16, 2010, by the Canadian Hereditary Angioedema Network (CHAEN) and cosponsors.
  • The consensus document was reviewed at the conference and subsequently circulated for further review.

Main Results:

  • The manuscript presents the 2010 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema.

Conclusions:

  • The current consensus approach serves as an interim guide for managing HAE.
  • The need for large-scale clinical trials (Phase III/IV), meta-analyses, registry validation, and head-to-head trials is highlighted.
  • Development of evidence-based guidelines and standards for HAE management is crucial.
Abstract

More Related Videos

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

Related Concept Videos

Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Aneurysm III: Interprofessional Care01:26

Aneurysm III: Interprofessional Care

Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...